Complementary and alternative therapies for Alzheimer's disease: A conference summary

Alzheimer's Care Quarterly

Volumn 7, Issue 1, 2006, Pages 13-31

  Pope, Sandra K ^a,b   Horne, M T ^b   Morris, M C ^c   Sano, M ^d   Gwyther, Lisa P ^e,f   Lombardo, N E ^g,h   Beck, C ^a,i   DeKosky, S T ^j,k  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Alzheimer's Disease Center   (United States)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Department of Pediatrics   (United States)

^j UNIVERSITY OF PITTSBURGH   (United States)

^k UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33745651561     PISSN: 15253279     EISSN: 15503240     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (85)

1. Alternative Medicine, Expanding Medical Horizons. A Report to the National Institutes of Health on Alternative Medical Systems and Practices in the United States. Washington, DC: US Govt Printing Office; 1992.
2. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. N Engl J Med. 1993;328(4): 246-252.
3. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997. JAMA. 1998;280(18):1569-1575.
4. Ervin RB, Wright JD, Reed-Gillette D. Prevalence of leading types of dietary supplements used in the Third National Health and Nutrition Examination Survey, 1988-1994. Adv Data. 2004;349:1-7.
5. Executive summary: Conference on Dietary Supplement Use in the Elderly; January 14-15, 2003. Natcher Auditorium, National Institutes of Health, Bethesda, MD. Washington, DC: International Lite Sciences Institute; 2004:160-175.
6. Coleman LM, Fowler LL, Williams ME. Use of unproven therapies by people with Alzheimer's disease. J Am Geriatr Soc. 1995;43(7):747-750.
7. Hogan DB, Ebly EM. Complementary medicine use in a dementia clinic population. Alzheimer Dis Assoc Disord. 1996;10(2):63-67.
8. DeKosky ST, Orgogozo JM.Alzheimer disease: diagnosis, costs, and dimensions of treatment. Alzheimer Dis Assoc Disord. 2001;15(suppl 1):S3-S7.
9. Sloan PD, Zimmerman S, Suchindran C, et al.The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health. 2002;23:213-231.
10. Pope SK, Shue VM, Beck C. Will a healthy lifestyle help prevent Alzheimer's disease? Annu Rev Public Health. 2004;24:111-132.
11. DeKosky ST. Epidemiology and pathophysiology of Alzheimer's disease. Clin Geriatr. 2001;3(4):15-26.
12. Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia. 2000;15:93-101.
13. Lopez OL, Jagust WJ, DeKosky ST. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003;60:1385-1389.
14. Lopez OL, Jagust WJ, Dulberg C. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol. 2003;60:1394-1399.
15. LeBars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA. 1997;278(16):1327-1332.
16. Retz W, Gsell W, Munch G, Rosler M, Riederer P. Free radicals in Alzheimer's disease J Neural Transm Suppl. 1998;54:221-236.
17. Luo Y, Smith JV, Paramasivam V. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA. 2002;99:12197-12202.
18. Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R. Ginkgo for memory enhancement. JAMA. 2002;288(7):835-840.
19. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol. 1998;55(11):1409-1415.
20. Andrieu S, Gillette S, Amouyal K, et al. Association of Alzheimer's disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EIP-DOS study. J Gerontol Med Sci. 2003;58A(4):372-377.
21. Birks J, Grimley EJ, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003.
22. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of health and human services task force on Alzheimer's disease. Neurology. 1984;34(7):939-944.
24. Behl C. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol. 1999;57:301-323.
25. Wu X, Beecher GR, Holden JM, Haytowitz DB, Gebhardt SE, Prior RL. Lipophilic and hydrophilic antioxidant capacities of common foods in the United States. J Agric Food Chem. 2004;52(12): 4026-4037.
26. Milgram NW, Zicker SC, Head E. Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Neurobiol Aging. 2002;23:737-745.
27. Joseph JA, Shukitt-Hale B, Denisova NA, et al. Long-term dietary strawberry, spinach or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits. J Neurosci. 1998;18:8047-8055.
28. Ezaki Y, Nishihara E, Shibata Y, et al. Vitamin E prevents the neuronal cell death by repressing cyclooxygenase-2 activity. Neuroreport. 2005;16(11):1163-1167.
29. Sung S, Yao Y, Uryu K, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J. 2004;18(2):323-325.
30. Parle M, Dhingra D. Ascorbic acid: a promising memory-enhancer in mice. J Psychol Theology. 2005;93(2):129-135.
31. Pettenuzzo LF, Schuck PF, Fontella F, et al. Ascorbic acid prevents cognitive deficits caused by chronic administration of propionic acid to rats in the water maze. Pharmacotherapy. 2005;73(3):623-629.
32. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997;336(17):1216-1222.
33. Petersen RC, Thomas RG, Grundman M. et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379- 2388.
34. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2A.D.; 360(9326):23-33.
35. Miller ERI, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.
36. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005; 293(11):1338-1347.
37. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol. 2004;61(1):82-88.
38. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA. 2002;287(24):3223-3229.
39. Morris MC, Evans DA, Bienias JL, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 2002;287(24):3230-3237.
40. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol. 2003;60(2):203-208.
41. Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology. 2000;54:1265-1272.
42. Cole GM, Morihara T, Lim GP, Yang F, Begum A, Frautschy SA. NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. Ann NY Acad Sci. 2004;1035:68-84.
43. Kalmijn S, Launer LJ, Ott A, Witteman JCM, Hofman A, Breteler MBM. Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann Neurol. 1997;42:776-782.
44. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Diet and risk of dementia: does fat matter?: the Rotterdam study. Neurology. 2004;59(12):1915- 1921.
45. Larrieu S, Letenneur L, Helmer C, Dartigues JF, Barberger-Gateau P. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J Nutr Health Aging. 2004;8(3):150-154.
46. Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003;60(7):940-946.
47. Notkola I, Sulkava R, Pekkanen J, et al. Serum total cholestrol, apolipoprotein E4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17:14-20.
48. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. Dietary fat intake and 6-year cognitive change in an older biracial community. Neurology. 2004;62(9):1573-1579.
49. Benson H, Beary JF, Carol MP. The relaxation response. Psychiatry. 1974;37:37-46.
50. Esch T, Stefano GB, Fricchione GL, Benson H. The role of stress in neurodegenerative diseases and mental disorders. Neuro Endocrinol Lett. 2002;23:199-208.
51. Jacobs GD. The physiology of mind-body interactions: the stress response and the relaxation response. J Altern Complement Med. 2001;7(suppl 1):S-83-S-92.
52. Davidson RJ, Kabat-Zinn J, Schumacher J, et al. Alterations in brain and immune function produced by mindfulness meditation. Psychosom Med. 2003;65: 564-570.
53. Roth B, Creaser T. Mindfulness meditation-based stress reduction: experience with a bilingual inner-city program. Nurse Pract. 1997;22(3):150-176.
54. Cooper M, Aygen M. Effect of meditation on blood cholesterol and blood pressure. Harefuah. 1978;95(1):1-2.
55. Schneider RH, Alexander CN, Wallace RK. In search of an optimal behavioral treatment for hypertension: a review and focus on transcendental meditation. In: Johnson EH, Gentry WD, Julius S, eds. Personality, Elevated Blood Pressure, and Essential Hypertension. Washington, DC: Hemisphere; 1992.
56. Speca M, Carlson LE, Goodey E, Angen M. A randomized, wait-list controlled clinical trial: the effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. Psychosom Med. 2000;62:613-622.
57. Kabat-Zinn J.An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. Gen Hosp Psychiatry. 1982;4: 33-47.
58. Kabat-Zinn J, Lip worth L, Burney R, Sellers W. Four-year follow-up of a meditation-based program for the self-regulation of chronic pain. Treatment outcomes and compliance. Clin J Pain. 1987;2(3):159-173.
59. Kabat-Zinn J, Chapman A, Salmon P. Relationship of cognitive and somatic components of anxiety to patient preference for different relaxation techniques. Mind/Body Med. 1997;2(3):101-109.
60. Reibel DK, Greeson JM, Brainard GC, Rosenzweig S. Mindfulness-based stress reduction and health-related quality of life in a heterogeneous patient population. Gen Hosp Psychiatry 2001;23:183-192.
61. Shapiro SL, Bootzin RR, Figueredo AJ, Lopez AM, Schwartz GE. The efficacy of mindfulness-based stress reduction in the treatment of sleep disturbance in women with breast cancer. An exploratory study. J Psychosom Res. 2003;54:85-91.
62. Waelde LC, Thompson L, Gallagher-Thompson D.A pilot study of a yoga and meditation intervention for dementia caregiver stress. J Clin Psychol. 2004;60(6):677-687.
63. Knight BG, Lutzky SM, Macofsky-Urban F. A meta-analytic review of interventions for caregiver distress: recommendations for future research. Gerontologist. 1993;33(2):240-248.
64. Schulz R, Beach SR. Caregiving as a risk factor for mortality. JAMA. 1999;282(23):2215-2219.
65. Gonzalez-Salvador MT, Arango C, Lyketsos CG, Barba AC. The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry. 1999;14(9):701-710.
66. Marcus MT, Fine PM, Moeller FG, et al. Change in stress levels following mindfulness-based stress reduction in a therapeutic community. Addict Disord Treat. 2003; 2(3):63-68.
67. Shapiro SL, Schwartz GE, Bonner G. Effects of mindfulness-based stress reduction on medical and premedical students. J Behav Med. 1998;21(6): 581-599.
68. Kabat-Zinn J, Lipworth L, Burney R. The clinical use of mindfulness meditation for the self-regulation of chronic pain. J Behav Med. 1985;8(2):163-190.
69. Kaplan KH, Goldenberg DL, Galvin-Nadeau M. The impact of a meditation-based stress reduction program on fibromyalgia. Gen Hosp Psychiatry. 1993;15(5):284-289.
70. Kabat-Zinn J, et al. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing photo-therapy (UVB) and photochemotherapy (PUVA). Psychosom Med. 1998; 60(5):625-632.
71. Lombardo NE. Acupuncture: a treatment for anxiety and depression in persons with dementia: results of a feasibility and effectiveness study. Alzheimer's Care Q. 2001;2:28-41.
72. Johansson BB.Acupuncture and transcutaneous nerve stimulation in stroke rehabilitation: a randomized, controlled trial. Stroke. 2001;32:707-713.
73. Kao H. Acupuncture enhancement in clinical symptoms and cognitive-motor abilities of the Alzheimer disease patients. Paper presented at:WorldAlzheimer's Conference July 9-18, 2000; Washington, DC.
74. Hanyi G, Lefa Y, Baibo L, et al. Clinical study on treatment of senile vascular dementia by acupuncture. J Tradit Chin Med. 2001;21(2):103-109.
75. Allen JJB, Schnyer RN, Hitt SK. The efficacy of acupuncture in the treatment of major depression in women. Psychol Sci. 1998;9:397-401.
76. Dong JT. Research on the reduction of anxiety and depression with acupuncture. Am J Acupunct. 1993;21:327-329.
77. Naeser MA. Neurological Rehabilitation: Acupuncture and Laser Acupuncture to Treat Paralysis in Stroke and Other Paralytic Conditions and Pain in Carpal Tunnel Syndrome. Bethesda, MD: National Institutes of Health, Office of the Director; 1997.
78. Chen Y. Clinical research on treating senile AD by combining acupuncture with acupoint-injection. Acupunct Electro. 1992;17(61):73.
79. Guo Y, Shi X, Uchiyama H, et al.A study on the rehabilitation of cognitive function and short-term memory in patients with Alzheimer's disease using transcutaneious electrical nerve stimulation. Front Med Biol Eng. 2002;11(4):237-247.
80. Teri L, Ferretti LE, Gibbons LE, et al. Anxiety in Alzheimer's disease: prevalence and cormorbidity. J Gerontol Med Sci. 1999;54A(7):M348-M352.
81. The Links Between Religion and Health: Are They Real? Washington, DC: Gerontological Society of America; 2002. Report No. 12(4).
82. Idler EL, Kasl SV. Religion among disabled and nondisabled persons, I: cross-sectional patterns in health practices, social activities, and well-being. J Gerontol B Psychol Sci Soc Sci. 1997;52(6): S294-S305.
83. Idler EL, Kasl SV. Religion among disabled and nondisabled persons, II: attendance at religious services as a predictor of the course of disability. J Gerontol Soc Sci. 1997;52B(6):S306-S316.
84. Lenshyn J. Reaching the living echo: maintaining and promoting the spiritual persons living with Alzheimer's disease. Alzheimer's Care Q. 2005;6(1):20-28.
85. Prior RL, Hoang H, Gu L, et al. Assays for hydrophilic and lipophilic antioxidant capacity (oxygen radical absorbance capacity (ORAC(FL))) of plasma and other biological and food samples. J Agric Food Chem. 2003;51(11):3273-3279.